A5088380177- Antibiotic Resistance in Bacteria
- Antibiotics Pharmacokinetics and Efficacy
- Antibiotic Use and Resistance
- Bacterial Identification and Susceptibility Testing
- Vibrio bacteria research studies
- Streptococcal Infections and Treatments
- Antimicrobial Resistance in Staphylococcus
- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
Hartford Hospital
2024-2025
University of Health Sciences Antigua
2024
Sağlık Bilimleri Üniversitesi
2020-2024
Şişli Etfal Eğitim ve Araştırma Hastanesi
2020-2024
Abstract Background Optimal antibiotic dosing in patients undergoing CRRT is influenced by many factors that affect drug adsorption and clearance. These include filter type, mode, effluent rate (ER), characteristics. FEP-TAN an investigational β-lactam/β-lactamase inhibitor combination having broad-spectrum activity against carbapenem-resistant Enterobacterales Pseudomonas aeruginosa. Both FEP TAN are primarily eliminated through glomerular filtration. Hence, we conducted ex vivo model to...
Abstract Background Acinetobacter baumannii-calcoaceticus complex (ABC) isolates are responsible for severe infections, such as bacteremia, healthcare-associated pneumonia, and skin soft tissue infections. Sulbactam-durlobactam is a FDA-approved targeted β-lactam-β-lactamase inhibitor combination antibiotic developed to treat infections caused by ABC. This study aims evaluate the in vitro activity of sulbactam-durlobactam clinically utilized antibiotics against ABC strains with predominance...
Abstract Background Due to the increasing prevalence of carbapenem-Resistant Pseudomonas aeruginosa (CRPA), effective agents are needed treat these serious infections. Although CRPA may test susceptible other β-lactams such as ceftazidime (CAZ), cefepime (FEP), and piperacillin/tazobactam (TZP), reduced potency has been observed amongst CRPA. In this study, we used PKPD analysis assess adequacy EUCAST Susceptible (S) or Increased Exposure (SIE)/(I) doses for CAZ, FEP, TZP against clinical...